Clinical Trials Logo

Filter by:
NCT ID: NCT06349044 Recruiting - Colorectal Cancer Clinical Trials

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

Start date: March 20, 2024
Phase: N/A
Study type: Interventional

Based on the interaction between radiation therapy and immunotherapy and the potential potentiation of Probio-M9 for the treatment of ICIs, this study is planned to design an integrated treatment protocol for the first-line treatment of advanced gastrointestinal tumors through the use of macrofractionated radiotherapy as a means of immune activation, combined with the synergistic effect of Probio-M9 microbial agents and PD-1 inhibitors.

NCT ID: NCT06348992 Recruiting - Clinical trials for Autism Spectrum Disorder

ACT Combined Yoga for Parental Burnout in Parents With Autistic Children

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

OBJECTIVE: To explore the intervention effect of ACT combined with a yoga intervention program on parenting burnout in parents with ASD. METHODS: This study used a combination of qualitative research and quantitative analysis to examine the intervention effects of an ACT-centered intervention program on parenting burnout in parents of children with ASD, and to clarify the evaluations and perceptions of parents with ASD about the research program through qualitative research. RESULTS AND CONCLUSION: To clarify the intervention effect of ACT combined with yoga intervention program on parenting burnout of ASD parents.

NCT ID: NCT06348407 Recruiting - Clinical trials for Moderate to Severe Allergic Asthma

A Clinical Study of Omalizumab in the Treatment of Allergic Asthma(ESSENCE)

ESSENCE
Start date: December 1, 2023
Phase:
Study type: Observational

Allergic asthma being the most widespread and easily identifiable phenotype, accounting for 60-80% of cases.Previous studies have reported that nearly 90% of patients with severe asthma were cases of allergic asthma, in which Immunoglobulin E (IgE) plays a critical role.Omalizumab was approved as an anti-IgE humanized monoclonal antibody for the treatment of patients with poorly controlled moderate-to-severe asthma, and was the first targeted drug used in the field of asthma treatment.The drug was launched in mainland China in August 2017.whereas,the clinical application experience, effects, and relevant data in the domestic population still lacking.The aim of this study was to observe the efficacy and safety of omalizumab, and to investigate whether baseline clinical characteristics and biomarkers can predicted response and adherence to treatment.

NCT ID: NCT06348381 Recruiting - Anastomotic Leak Clinical Trials

Prediction of Anastomotic Complications and Recurrent Laryngeal Nerve Injury Based on Postoperative Early Endoscopic Evaluation

Start date: April 1, 2024
Phase:
Study type: Observational

Analyze the correlation between the conformity of the anatomy (based on endoscopic examination) and postoperative anastomotic fistula and anastomotic stenosis; establish an anastomotic classification; and construct a predictive model combined with perioperative-related test indicators to provide more accurate risk assessment for clinical practice. Analyze the natural recovery process of postoperative recurrent laryngeal nerve injury in esophageal cancer by tracking vocal cord movement (based on endoscopic examination) and hoarseness symptoms; combined with perioperative related surgical and laboratory indicators, identify the relevant risk factors associated with delayed recovery of recurrent laryngeal nerve injury.

NCT ID: NCT06348264 Recruiting - Clinical trials for Salivary Gland Neoplasm Duct

Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma

Start date: March 30, 2024
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy (ADT) in participants with androgen receptor (AR) positive, high-risk salivary duct carcinoma (SDC). The procedures include screening, treatment and follow-up period. The treatment includes rezvilutamide plus Luteinizing Hormone Releasing Hormone agonist (LHRHa) for up to 2 years.

NCT ID: NCT06347770 Recruiting - Microbiota Clinical Trials

Effect of Probiotics Before Cesarean Section on Postoperative Recovery in Pregnant Women

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

This study aims to evaluate the effect of probiotics 7 days before cesarean section (CS) on postoperative recovery and the change of gut microbiota in pregnant women. Samples were obtained from a total of 80 pregnant individuals, divided into control group and probiotics group. Anal exhaust time and first defecating time were set as the primary outcome of recovery of CS. 16S rRNA amplicon sequencing of the V4 region was analyzed to evaluate the composition of them.

NCT ID: NCT06347679 Recruiting - Dental Anxiety Clinical Trials

Effects of Aromatherapy on Anxiety and Pain During Dental Treatment in Adults

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

Dental anxiety is a common problem in dental care. The aim of this protocol is to evaluate the effect of orange and tea essential oil for the control of anxiety and pain in adults during dental treatments.

NCT ID: NCT06347653 Recruiting - Clinical trials for Nodal T-follicular Helper Cell Lymphoma

Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL)

Start date: November 28, 2023
Phase: Phase 2
Study type: Interventional

This study is conducted to evaluate the efficacy and safety of linperlisib combined with CHOP regimen followed by autologous hematopoietic stem cell transplantation and linperlisib monotherapy maintenance for newly diagnosed nTFHL patients.

NCT ID: NCT06347523 Recruiting - Clinical trials for Anterior Cruciate Ligament (ACL) Reconstruction

VR-Based Preoperative Rehabilitation Program for Patients Undergoing Anterior Cruciate Ligament (ACL) Reconstruction

Start date: April 2, 2024
Phase: N/A
Study type: Interventional

Between April 2, 2024, and October 1, 2024, a study will be conducted at the Department of Orthopedics in the First Affiliated Hospital of Shantou University Medical College involving 120 patients who will undergo anterior cruciate ligament reconstruction surgery. They will be randomly divided into two groups: an experimental group and a control group.

NCT ID: NCT06347276 Recruiting - Thrombosis Cardiac Clinical Trials

Cerebral Microembolization Associated With PFO Closure

Start date: January 1, 2024
Phase:
Study type: Observational

This study aims to investigate (1) the de novo cerebral microembolization in patients who undergo transcatheter closure of PFO or ASD, and (2) evaluate the relationship between de novo cerebral microembolization and in situ thrombus within PFO.